15 completed. 15 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 4 | Completed 4 |
Follow Alopecia Areata: new trials by email Literature Review of Alopecia Areata trials Research Report on Alopecia Areata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. Tofacitinib - Alopecia Areata, Alopecia Totalis | Phase 3 | Completed | Jinnah Hospital | 30 | 2023-07-01 | 2024-02-26 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 315 | 2022-03-25 | 2025-03-18 |
| European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata CTP-543 - Alopecia Areata | Phase 3 | Completed | Sun Pharmaceutical Industries, Inc. | 407 | 2021-10-19 | 2025-11-21 |
| Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib, placebo - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 425 | 2021-09-04 | 2025-03-14 |
| Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) CTP-543 matching placebo, CTP-543 - Alopecia Areata | Phase 3 | Completed | Concert Pharmaceuticals | 517 | 2021-06-10 | 2023-07-03 |
| Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) CTP-543 matching placebo, CTP-543 - Alopecia Areata | Phase 3 | Completed | Concert Pharmaceuticals | 706 | 2020-11-23 | 2023-05-03 |
| Long-Term PF-06651600 for the Treatment of Alopecia Areata PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine - Alopecia Areata | Phase 3 | Completed | Pfizer | 1057 | 2019-07-18 | 2026-04-09 |
| A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Baricitinib, Placebo - Alopecia Areata | Phase 3 | Completed | Eli Lilly and Company | 606 | 2019-07-08 | 2026-04-07 |
| PF-06651600 for the Treatment of Alopecia Areata PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2 - Alopecia Areata | Phase 2 / Phase 3 | Completed | Pfizer | 718 | 2018-12-03 | 2022-02-24 |
| A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Baricitinib, Placebo - Alopecia Areata | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 784 | 2018-09-24 | 2026-04-16 |
| Efficacy and Safety of LH-8 in Paediatric Alopecia Areata LH-8, Placebo - Alopecia Areata, Pediatric Disorder | Phase 2 / Phase 3 | Completed | Legacy Healthcare SA | 107 | 2018-02-01 | 2023-12-12 |
| TREg Activation in the Treatment of the PELADE (Alopecia Areata) IL2, placebo - Alopecia Areata | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 44 | 2015-12-15 | 2026-03-24 |
| The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Methotrexate, Placebo - ALOPECIA AREATA | Phase 3 | Completed | University Hospital, Rouen | 90 | 2014-02-01 | 2018-05-29 |
| Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Targretin Gel 1% - Alopecia Areata | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 46 | 2003-05-01 | 2012-08-02 |
| A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Hydrocortisone 1%, Clobetasol Propionate 0.05% - Alopecia Areata | Phase 3 | Completed | The Hospital for Sick Children | 41 | 2002-08-01 | 2013-12-09 |
Alopecia (4) · Alopecia universalis (4) · Hair Diseases (3)
Hypotrichosis (15) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Hair Diseases (12) · Alopecia (11) · Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4)
baricitinib (2) · Bexarotene (1) · Interleukin-2 (1) · Methotrexate (1) · PF-06651600 (1) · Tetanus Toxoid (1) · Vaccines (1) · tofacitinib (1)
Concert Pharmaceuticals (2) · Eli Lilly and Company (2) · Pfizer (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Centre Hospitalier Universitaire de Nice (1) · Jinnah Hospital (1) · Legacy Healthcare SA (1) · M.D. Anderson Cancer Center (1) · Sun Pharmaceutical Industries, Inc. (1) · The Hospital for Sick Children (1) · University Hospital, Rouen (1)
United States (7) · France (6) · Canada (5) · China (5) · Germany (5) · Poland (5) · Spain (5) · Japan (4) · South Korea (4) · Argentina (3) · Australia (3) · Hungary (3) · Mexico (3) · Taiwan (3) · Chile (2)
Colin Macarthur, MBChB, PhD (1) · Ishad Aggarwal, Dr (1) · Jason Wu (1) · Jianzhong Zhang, PhD (1) · Madeleine Duvic, MD (1) · Maya Milanova, Dr (1) · Passeron Thierry, PUPH (1) · Petyo Brezoev, Dr. (1) · Qianjin Lu, PhD (1)
PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37991697, PMID 38263353, PMID 38904749, PMID 39962358, PMID 40214720, PMID 41917311, PMID 42481842, PMID 42823604, PMID 42825995, PMID 24226568, PMID 24940651, PMID 28139263, PMID 28300084, PMID 29273099, PMID 31799258, PMID 32941917, PMID 34211288, PMID 36177791, PMID 36884234, PMID 37062298, PMID 37339501, PMID 37403610, PMID 37521227, PMID 37707764, PMID 37917289, PMID 37955531, PMID 39053611, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39423930, PMID 39432738, PMID 39441519, PMID 39846397, PMID 40261547, PMID 40668972, PMID 41005700, PMID 41317911, PMID 41579233, PMID 41645877
2018 (1), 2023 (1)